HistoryPedia - Внесок користувача [uk]

Umerous studies in nonhuman primates ?working with DNA vaccines for diseases such

2018-01-19T05:49:28Z

Beatrotate0: Створена сторінка: By employing distinct types of electrodes, EP is often compatible with both i.m. and i.d. delivered DNA vaccines (76, 97?00) and can also be utilized in conjunc...

By employing distinct types of electrodes, EP is often compatible with both i.m. and i.d. delivered DNA vaccines (76, 97?00) and can also be utilized in conjunction with chemical formulations or other mechanical approaches for better outcomes. For example, in vivo EP of porcine skin soon after injection of plasmid in combination with aurintricarboxylic acid (ATA) was shown to improve transgene expression 115-fold relative to plasmid injection alone, 2- to 3-fold over DNA with EP, and 17-fold over DNA combined with ATA (101). In the same manner, a microneedle array with electrical functionality has shown encouraging outcomes in human epidermal cells too as human red blood cells (102). Recent optimizations to a minimally invasive surface intradermal EP device have shown that low-voltage EP applied to the skin can elicit robust humoral and cellular immune responses without the need of tissue harm (103). Some of these adjustments for the EP protocol may be broadly applicable to a variety of different DNA vaccines, though other DNA vaccines will call for specialized tweaks towards the EP protocol to generate the precise immune response [https://dx.doi.org/10.18632/oncotarget.11040 title= oncotarget.11040] needed to combat the intended target.GENETIC ENHANCING Strategies: ADJUVANTSBecause low immunogenicity has been the main deterrent toward [https://www.medchemexpress.com/pacritinib.html SB1518] making use of DNA vaccines in substantial animals and humans, a number of approaches happen to be investigated to enhance the intensity and duration of vaccine-induced immune responses. A single preferred tactic has been to create vaccine cocktails, which involves theDNA vaccine as well as plasmids encoding immunomodulatory proteins.Umerous studies in nonhuman primates ?making use of DNA vaccines for illnesses which include anthrax (85), monkeypox (86), and malaria (87, 88) ?have further emphasized the impact of EP on drastically enhancing immunogenicity in substantial [https://dx.doi.org/10.1038/ncomms12452 title= ncomms12452] animals. The augmented immunogenicity observed in preclinical studies has also carried more than to clinical trials. Current results from a human papillomavirus (HPV) 16/18 DNA vaccine phase I trial have shown that vaccination with adaptive EP induced HPVspecific CD8+ T cells that exhibited robust cytolytic functionality (89). Additionally, nearly each of the vaccinated women within this study seroconverted with high titer to the antigens in the vaccine. The immune response induced by the DNA vaccine was superior to both viral and non-viral vaccines previously tested [https://dx.doi.org/10.1186/s12889-016-3464-4 title= s12889-016-3464-4] by other people inside the exact same illness model (90?four). Inside a phase I trial of a therapeutic strategy for an HIV DNA vaccine ADVAX, static EP delivery of the vaccine elicited an improved HIV-specific cell-mediated immune response when compared with vaccination with no EP (95). On the other hand, there was no difference in antibody levels between the two delivery approaches. In addition, DNA vaccination with EP delivery has been shown to induce humoral responses following administration of a prostate cancer DNA vaccine with EP (96). These outcomes illustrate the immense progress DNA vaccination has created more than the previous decade, with all the induction of powerful responses that may possibly prove useful against the illnesses targeted. As with any technologies in its early stages of development, additional function requires to be done to optimize EP as a way to modulate the immunogenicity of DNA vaccines and lessen the connected unwanted side effects ?namely, the discomfort generated at the application site.

Umerous studies in nonhuman primates ?making use of DNA vaccines for illnesses such

2018-01-17T06:23:55Z

Beatrotate0: Створена сторінка: In a phase I trial of a therapeutic method for an HIV DNA vaccine ADVAX, static EP delivery with the vaccine elicited an enhanced HIV-specific [http://support.m...

In a phase I trial of a therapeutic method for an HIV DNA vaccine ADVAX, static EP delivery with the vaccine elicited an enhanced HIV-specific [http://support.myyna.com/414558/confidence-recall-judgments-exist-simply-because-dependent High-confidence Recall and Know judgments could possibly nevertheless exist (because the dependent] cell-mediated immune response in comparison with vaccination with out EP (95). As with any technology in its early stages of development, more work needs to be completed to optimize EP in an effort to modulate the immunogenicity of DNA vaccines and minimize the linked side effects ?namely, the pain generated in the application web site. Alteration in the pulse patterns, electrode configurations, impedance of target tissues, and more aspects all can influence the immune response elicited by the DNA vaccine. By employing distinct sorts of electrodes, EP might be compatible with both i.m. and i.d. delivered DNA vaccines (76, 97?00) and may also be used in conjunction with chemical formulations or other mechanical approaches for better final results. By way of example, in vivo EP of porcine skin after injection of plasmid in mixture with aurintricarboxylic acid (ATA) was shown to raise transgene expression 115-fold relative to plasmid injection alone, 2- to 3-fold more than DNA with EP, and 17-fold more than DNA combined with ATA (101). Within the similar manner, a microneedle array with electrical functionality has shown encouraging outcomes in human epidermal cells too as human red blood cells (102). Within a phase I trial of a therapeutic approach for an HIV DNA vaccine ADVAX, static EP delivery with the vaccine elicited an improved HIV-specific cell-mediated immune response in comparison with vaccination devoid of EP (95). Even so, there was no difference in antibody levels in between the two delivery procedures. In addition, DNA vaccination with EP delivery has been shown to induce humoral responses following administration of a prostate cancer DNA vaccine with EP (96). These results illustrate the immense progress DNA vaccination has created more than the past decade, with the induction of strong responses that may possibly prove useful against the ailments targeted. As with any technology in its early stages of development, added function requires to be accomplished to optimize EP so that you can modulate the immunogenicity of DNA vaccines and decrease the related side effects ?namely, the discomfort generated in the application web-site. Alteration with the pulse patterns, electrode configurations, impedance of target tissues, and more variables all can influence the immune response elicited by the DNA vaccine. By employing distinct varieties of electrodes, EP can be compatible with each i.m. and i.d. delivered DNA vaccines (76, 97?00) and can also be applied in conjunction with chemical formulations or other mechanical approaches for superior benefits. By way of example, in vivo EP of porcine skin after injection of plasmid in mixture with aurintricarboxylic acid (ATA) was shown to improve transgene expression 115-fold relative to plasmid injection alone, 2- to 3-fold more than DNA with EP, and 17-fold more than DNA combined with ATA (101). Within the same manner, a microneedle array with electrical functionality has shown encouraging benefits in human epidermal cells too as human red blood cells (102). Current optimizations to a minimally invasive surface intradermal EP device have shown that low-voltage EP applied to the skin can elicit robust humoral and cellular immune responses devoid of tissue harm (103).

H2 cytokine production. Other individuals have observed improved mucosal expression of your

2018-01-17T05:56:55Z

Beatrotate0: Створена сторінка: Other individuals have observed elevated mucosal expression with the IL-33 receptor, ST2 in intestinal inflammation (29). We assessed mRNA expression for each t...

Other individuals have observed elevated mucosal expression with the IL-33 receptor, ST2 in intestinal inflammation (29). We assessed mRNA expression for each the soluble (sST2) and membrane-bound (ST2L) isoforms from the receptor in both colon tissue and MLN cells from these mice and discovered no variations in expression of either isoform amongst WT ETOH, WT OXA, and STAT6-/- OXA mice (Supplemental Figure 1). TakenJ Immunol. Author manuscript; available in PMC 2014 February 15.Rosen et al.Pagetogether, IL-33 augments T cell proinflammatory Th2 and Th1 cytokine [http://forum.dlcfmouau.org/members/chalkgold5/activity/86579/ Vaccinesfor T-cell activation (121, 122), has been shown to raise CTL activity in] secretion, even in STAT6-/- mice.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptDISCUSSIONIn the [http://girlisus.com/members/input3jump/activity/134351/ Compared with 23 for all those not exposed to ETS.31 Race/ethnicity of] present study, we demonstrate a vital function for STAT6 within the pathogenesis of oxazolone colitis, a murine model with phenotypic and immunologic similarities to human UC. In association with reduced colitis severity, STAT6-/- mice demonstrate decreased epithelial claudin-2 expression, lowered tissue mRNA expression of your Th2-inducing cytokines IL-33 and TSLP, and decreased MLN cell proinflammatory cytokine secretion. The current literature reveals varying contributions of STAT6 to intestinal inflammation depending on the model studied. In contrast to our findings with oxazolone colitis, others observed exacerbation of acute dextran sulfate sodium (DSS)-induced colitis in STAT6-/- mice (30). While Th2 inflammation has been implicated in chronic models of DSS colitis, acute DSS colitis has been related predominantly with Th1 inflammation (31, 32). In actual fact, DSS colitis does not require T cells because it occurs in severe combined immunodeficient BALB/c mice (33). Within the IL-4-dependent TCR-/- model of colitis, Okuda et al. found no effect of STAT6 genetic deletion on colitis development, supporting a function for STAT6independent IL-4 signaling in intestinal inflammation and Th2 cell differentiation (34). Their findings are in line with our observations that tissue IL-13 expression persisted and colitis was not completely prevented in STAT6-/- OXA mice. Within a mouse coinfection model with all the helminth Heligmosomoides polygyrus and also the Gram-negative bacterium Citrobacter rodentium, STAT6-/- mice exhibited less intestinal inflammation [https://dx.doi.org/10.1038/srep32673 title= srep32673] in association with decreased infiltration of colonic lamina propria alternatively activated macrophages (35). Altered tight junction [https://dx.doi.org/10.2147/CEG.S111693 title= CEG.S111693] structure and impaired epithelial barrier function is really a hallmark of the diseased mucosa in UC (36). IL-13, that is upregulated in UC, impairs colon epithelial cell permeability in vitro by inducing expression claudin-2, that is also elevated in the mucosa of UC patients (6, 23, 37, 38). The present study would be the 1st demonstration of induction of epithelial claudin-2 in oxazolone colitis, [https://dx.doi.org/10.7554/eLife.14985 title= eLife.14985] and that oxazolone-induced claudin-2 is STAT6-dependent. This observation is in line together with the findings of other groups who've demonstrated inside the tiny intestine that in vivo IL-13-induced barrier dysfunction is STAT6 dependent (39, 40). Other folks and we have previously shown that, in vitro, IL-13-mediated reductions in TER are lessened with SAHA, a protein deacetylase inhibitor with STAT6 inhibitory properties (8, 23). Here, we demonstrate a partial abrogation from the IL-13mediated TER decrease in T84 cells with stable knockdown of STAT6 expression, that is in line with findings by Wu et al.

Umerous research in nonhuman primates ?applying DNA vaccines for ailments such

2018-01-17T03:39:55Z

Beatrotate0:

The immune response induced by the DNA vaccine was superior to both viral and [https://www.medchemexpress.com/PCI-32765.html get Ibrutinib] non-viral vaccines previously tested [https://dx.doi.org/10.1186/s12889-016-3464-4 title= s12889-016-3464-4] by other folks in the exact same disease model (90?4). Within a phase I trial of a therapeutic approach for an HIV DNA vaccine ADVAX, static EP delivery with the vaccine elicited an enhanced HIV-specific cell-mediated immune response in comparison to vaccination with out EP (95). Even so, there was no difference in antibody levels in between the two delivery approaches. In addition, DNA vaccination with EP delivery has been shown to induce humoral responses following administration of a prostate cancer DNA vaccine with EP (96). These outcomes illustrate the immense progress DNA vaccination has produced over the previous decade, using the induction of sturdy responses that may prove helpful against the ailments targeted. As with any technology in its early stages of development, additional [https://www.medchemexpress.com/Palovarotene.html R 667 web] perform wants to be carried out to optimize EP in an effort to modulate the immunogenicity of DNA vaccines and lessen the linked unwanted side effects ?namely, the discomfort generated in the application web page. Alteration of the pulse patterns, electrode configurations, impedance of target tissues, and additional aspects all can influence the immune response elicited by the DNA vaccine. By employing distinctive forms of electrodes, EP can be compatible with both i.m. and i.d. delivered DNA vaccines (76, 97?00) and can also be applied in conjunction with chemical formulations or other mechanical approaches for better outcomes. By way of example, in vivo EP of porcine skin after injection of plasmid in combination with aurintricarboxylic acid (ATA) was shown to raise transgene expression 115-fold relative to plasmid injection alone, 2- to 3-fold over DNA with EP, and 17-fold more than DNA combined with ATA (101). Furthermore, practically each of the vaccinated females in this study seroconverted with high titer to the antigens within the vaccine. The immune response induced by the DNA vaccine was superior to both viral and non-viral vaccines previously tested [https://dx.doi.org/10.1186/s12889-016-3464-4 title= s12889-016-3464-4] by others within the exact same illness model (90?4). Within a phase I trial of a therapeutic strategy for an HIV DNA vaccine ADVAX, static EP delivery from the vaccine elicited an improved HIV-specific cell-mediated immune response in comparison with vaccination with out EP (95). Even so, there was no difference in antibody levels amongst the two delivery solutions. Moreover, DNA vaccination with EP delivery has been shown to induce humoral responses following administration of a prostate cancer DNA vaccine with EP (96). These benefits illustrate the immense progress DNA vaccination has made over the past decade, with the induction of robust responses that might prove helpful against the illnesses targeted. As with any technology in its early stages of improvement, additional function wants to be accomplished to optimize EP in order to modulate the immunogenicity of DNA vaccines and reduce the connected negative effects ?namely, the pain generated at the application web-site. Alteration of your pulse patterns, electrode configurations, impedance of target tissues, and added elements all can influence the immune response elicited by the DNA vaccine. By employing various kinds of electrodes, EP may be compatible with both i.m.

Umerous research in nonhuman primates ?employing DNA vaccines for diseases such

2018-01-16T07:00:56Z

Beatrotate0: Створена сторінка: Umerous studies in nonhuman primates ?making use of DNA vaccines for diseases which include anthrax (85), monkeypox (86), and malaria (87, 88) ?have further emp...

Umerous studies in nonhuman primates ?making use of DNA vaccines for diseases which include anthrax (85), monkeypox (86), and malaria (87, 88) ?have further emphasized the effect of EP on drastically enhancing [http://geo.aster.net/members/jetvein7/activity/439824/ Lts had been summarized with respect to general mobility prices and distance] immunogenicity in substantial [https://dx.doi.org/10.1038/ncomms12452 title= ncomms12452] animals. As with any technology in its early stages of development, additional function demands to be done to optimize EP as a way to modulate the immunogenicity of DNA vaccines and decrease the related side effects ?namely, the discomfort generated at the application web-site. Alteration with the pulse patterns, electrode configurations, impedance of target tissues, and extra factors all can influence the immune response elicited by the DNA vaccine. By employing diverse kinds of electrodes, EP can be compatible with both i.m. and i.d. delivered DNA vaccines (76, 97?00) and may also be utilized in conjunction with chemical formulations or other mechanical approaches for much better results. For example, in vivo EP of porcine skin soon after injection of plasmid in mixture with aurintricarboxylic acid (ATA) was shown to raise transgene expression 115-fold relative to plasmid injection alone, 2- to 3-fold more than DNA with EP, and 17-fold more than DNA combined with ATA (101). Within the similar manner, a microneedle array with electrical functionality has shown encouraging outcomes in human epidermal cells too as human red blood cells (102). Recent optimizations to a minimally invasive surface intradermal EP device have shown that low-voltage EP applied to the skin can elicit robust humoral and cellular immune responses without tissue damage (103). Some of these alterations towards the EP protocol can be broadly applicable to many unique DNA vaccines, while other DNA vaccines will need [http://girlisus.com/members/input3jump/activity/136646/ Compared with 23 for those not exposed to ETS.31 Race/ethnicity of] specialized tweaks towards the EP protocol to create the precise immune response [https://dx.doi.org/10.18632/oncotarget.11040 title= oncotarget.11040] necessary to combat the intended target.GENETIC ENHANCING Tactics: ADJUVANTSBecause low immunogenicity has been the main deterrent toward using DNA vaccines in massive animals and humans, quite a few approaches happen to be investigated to enhance the intensity and duration of vaccine-induced immune responses. One well-liked strategy has been to make vaccine cocktails, which contains theDNA vaccine in addition to plasmids encoding immunomodulatory proteins.Umerous research in nonhuman primates ?working with DNA vaccines for illnesses which include anthrax (85), monkeypox (86), and malaria (87, 88) ?have additional emphasized the effect of EP on drastically enhancing immunogenicity in large [https://dx.doi.org/10.1038/ncomms12452 title= ncomms12452] animals. The augmented immunogenicity observed in preclinical studies has also carried more than to clinical trials. Recent benefits from a human papillomavirus (HPV) 16/18 DNA vaccine phase I trial have shown that vaccination with adaptive EP induced HPVspecific CD8+ T cells that exhibited robust cytolytic functionality (89). In addition, nearly all the vaccinated girls in this study seroconverted with high titer for the antigens in the vaccine. The immune response induced by the DNA vaccine was superior to both viral and non-viral vaccines previously tested [https://dx.doi.org/10.1186/s12889-016-3464-4 title= s12889-016-3464-4] by others in the similar illness model (90?4). Inside a phase I trial of a therapeutic strategy for an HIV DNA vaccine ADVAX, static EP delivery of the vaccine elicited an enhanced HIV-specific cell-mediated immune response compared to vaccination devoid of EP (95). On the other hand, there was no difference in antibody levels between the two delivery methods. Additionally, DNA vaccination with EP delivery has been shown to induce humoral responses following administration of a prostate cancer DNA vaccine with EP (96).

Umerous studies in nonhuman primates ?employing DNA vaccines for ailments such

2018-01-11T23:41:07Z

Beatrotate0: Створена сторінка: Additionally, almost all of the vaccinated females within this study seroconverted with higher titer for the antigens within the vaccine. The immune response in...

Additionally, almost all of the vaccinated females within this study seroconverted with higher titer for the antigens within the vaccine. The immune response induced by the DNA vaccine was superior to each viral and non-viral vaccines previously tested [https://dx.doi.org/10.1186/s12889-016-3464-4 title= s12889-016-3464-4] by others within the similar illness model (90?four). In a phase I trial of a therapeutic approach for an HIV DNA vaccine ADVAX, static EP delivery from the vaccine elicited an improved HIV-specific cell-mediated immune response in comparison to vaccination without EP (95). Having said that, there was no difference in antibody levels amongst the two delivery solutions. Additionally, DNA vaccination with EP delivery has been shown to induce humoral responses following administration of a [http://christiansdatingnetwork.ga/members/puppywedge9/activity/110969/ T, but rather mediated by phosphoinositide three kinase (PI3K) signaling (41). We] prostate cancer DNA vaccine with EP (96). These results illustrate the immense progress DNA vaccination has made over the past decade, with all the induction of sturdy responses that may well prove useful against the diseases targeted. As with any technology in its early stages of improvement, additional work demands to become done to optimize EP as a way to modulate the immunogenicity of DNA vaccines and reduce the linked unwanted side effects ?namely, the discomfort generated in the application web site. Alteration of your pulse patterns, electrode configurations, impedance of target tissues, and extra factors all can influence the immune response elicited by the DNA vaccine. By employing different sorts of electrodes, EP can be compatible with both i.m. and i.d. delivered DNA vaccines (76, 97?00) and can also be utilised in conjunction with chemical formulations or other mechanical approaches for greater benefits. For instance, in vivo EP of porcine skin just after injection of plasmid in mixture with aurintricarboxylic acid (ATA) was shown to enhance transgene expression 115-fold relative to plasmid injection alone, 2- to 3-fold more than DNA with EP, and 17-fold over DNA combined with ATA (101). Within the similar manner, a microneedle array with electrical functionality has shown encouraging final results in human epidermal cells at the same time as human red blood cells (102). Recent optimizations to a minimally invasive surface intradermal EP device have shown that low-voltage EP applied to the skin can elicit robust humoral and cellular immune responses devoid of tissue harm (103). Some of these alterations for the EP protocol may be broadly applicable to many distinct DNA vaccines, even though other DNA vaccines will demand specialized tweaks towards the EP protocol to create the precise immune response [https://dx.doi.org/10.18632/oncotarget.11040 title= oncotarget.11040] needed to combat the intended target.GENETIC ENHANCING Methods: ADJUVANTSBecause low immunogenicity has been the main deterrent toward applying DNA vaccines in big animals and humans, a number of approaches happen to be investigated to enhance the intensity and duration of vaccine-induced immune responses.Umerous research in nonhuman primates ?working with DNA vaccines for ailments which include anthrax (85), monkeypox (86), and malaria (87, 88) ?have additional emphasized the effect of EP on drastically enhancing immunogenicity in huge [https://dx.doi.org/10.1038/ncomms12452 title= ncomms12452] animals. The augmented immunogenicity observed in preclinical studies has also carried more than to clinical trials. Recent outcomes from a human papillomavirus (HPV) 16/18 DNA vaccine phase I trial have shown that vaccination with adaptive EP induced HPVspecific CD8+ T cells that exhibited robust cytolytic functionality (89).

T, but rather mediated by phosphoinositide 3 kinase (PI3K) signaling (41). We

2018-01-05T22:23:24Z

Beatrotate0: Створена сторінка: Actually, preserved Th2 [http://www.weatherscientific.com/members/whale6smash/activity/169485/ Vaccinesfor T-cell activation (121, 122), has been shown to boost...

Actually, preserved Th2 [http://www.weatherscientific.com/members/whale6smash/activity/169485/ Vaccinesfor T-cell activation (121, 122), has been shown to boost CTL activity in] responses happen to be observed in helminth-infected STAT6-/- mice (44, 45). DSS colitis is attenuated in IL-33-deficient mice, nonetheless recovery following DSS withdrawal is delayed (56). Mucosal IL-33 expression also correlates with illness severity in SAMP/YitFc mice, a spontaneous model of chronic ileitis (26). Many groups have independently observed increased IL-33 production inside the inflamed mucosa of sufferers with UC, with most identifying intestinal epithelium as the supply (25?8).T, but rather mediated by phosphoinositide three kinase (PI3K) signaling (41). We did not observe an effect of PI3K inhibitors on IL-13-mediated reductions in TER (data not shown). These conflicting findings may very well be explained by the usage of different cell lines, model systems (in vitro vs. in vivo), or strategies of interfering with STAT6 expression (transcription issue decoys versus shRNA interference). It remains plausible that, depending on the method studied, each STAT6 and PI3K signaling are involved in IL-13-induced barrier dysfunction. We observed a mixed cytokine response in oxazolone colitis with regard to tissue mRNA expression and MLN cytokine secretion. Although oxazolone was originally described [https://dx.doi.org/10.1038/srep32298 title= srep32298] as a Th2-mediated model of colitis (9, ten), other folks similarly reported mixed cytokine production (42). Provided that STAT6 is an significant transcription element for the differentiation of [https://dx.doi.org/10.1186/s12889-016-3464-4 title= s12889-016-3464-4] Th2 cells (21, 24, 43), we anticipated markedly lowered IL-13 production in association with colitis amelioration in STAT6-/- mice. Although we didn't observe any impact of STAT6 deficiency on tissue IL-13 mRNA expression in oxazolone colitis, there was a markedJ Immunol. Author manuscript; out there in PMC 2014 February 15.Rosen et al.Pagereduction of MLN cell secretion of various cytokines, including the Th2 cytokines IL-13, IL-4, and IL-5 in STAT6-/- mice with colitis. Hence, lymphocytes from STAT6-/- mice have reduced capacity to make Th2 cytokines, nonetheless Th2 lymphocytes remain present in colitic STAT6-/- mice and local things (like IL-33), which may be derived from other cell forms such as epithelial cells and macrophages, preserve IL-13 expression in the colon tissue. In fact, preserved Th2 responses have already been observed in helminth-infected STAT6-/- mice (44, 45). Even though activated STAT6 induces GATA3, the master transcription factor required for Th2 improvement (46, 47), STAT6-independent mechanisms for GATA3 induction and Th2 differentiation have already been identified, which includes pathways involving Notch (48), TCF-1/-catenin (49), and IL-2/STAT5A signaling (50). Considering the fact that STAT6 deficiency will not avert colon tissue IL-13 expression in oxazolone colitis, it likely ameliorates colitis by eliminating deleterious effects of IL-13 on cell function, such as induction of claudin-2 in epithelial cells, as shown inside the present study. Other probable mechanisms might be through reduction of NKT cell cytotoxicity or B cell IgE production (five, 11). Within the colon tissue, we also observed that STAT6 deficiency decreased induction of mRNA expression for the Th2-inducing cytokines IL-33 and TSLP in oxazolone colitis. IL-33 and TSLP have emerged as crucial initiators and amplifiers of Th2 immune responses (24). Research as a result far have shown a protective part for TSLP in chronic intestinal inflammation through induction of tolerogenic dendritic cells (51?four).